The 21st China Medical Industry Summit Forum is held

With the continuous development of molecular biology technology, genetic engineering technology and gene editing technology, cell and gene therapy applications have achieved a series of breakthrough progress. Cell and gene therapy drug varieties are developing, production, quality control, application and industrialization of research, production, quality control, and industrialization. There are few precedents to follow, facing huge challenges and uncertainty. Recently, the thinking of cell and gene therapy drug development challenges and innovation solutions -the 21st China Medical Industry Summit Forum was successfully held in Nansha Industrial Park, Guangdong Medical Valley.

There are nearly 100 representatives from government agencies, biotechnology enterprises, investment institutions, industry associations, hospital/universities, service consulting institutions, scientific research institutions, etc., and gather together to interpret the challenges of cells and gene therapy drug development. Essence

Huang Qingnan, chairman of the Nansha District Science and Technology Association of Guangzhou City, said in his speech that the National Science Popularization Day is about to start. The science popularization activity is the good social atmosphere of love, science, science, science, and science. It is an excellent form of promoting the scientific spirit, spreading scientific ideas, and advocating the scientific and civilized lifestyle.

Huang Qingnan, Chairman of the Nansha District Science and Technology Association of Guangzhou City

He Jiechang, Deputy Bureau of the Health and Health Bureau of Nansha District, Guangzhou, fully expounded the importance of scientific research and innovation in the development of the biomedical industry in my country. Only by innovation from the source can we develop the original Chinese innovative medicine and lead in the international market. The official release of the "Nansha Plan" pointed out the direction for the high -quality development of Nansha's industry and injecting new strong motivation into it. At the same time, it also hoped that more biotechnology companies would come to Nansha to invest in the industry.

He Jiechang, Deputy Bureau of the Health and Health Bureau of Nansha District, Guangzhou

Xie Jiasheng, executive president of Guangdong Medical Valley, said that Guangdong Medical Valley has cultivated biomedicine for many years and has worked hard to create a China -Chuang Max+industrial service system. Among them, the multilateral resource sharing platform will hold nearly 50 industry activities each year, providing a professional communication platform for the industry to provide a professional communication platform for the industry Become a new trend of industry communication and communication, bringing positive energy and positive motivation to the industry. At the same time, the high -quality industrial services of Guangdong Medical Valley have also attracted more than 300 biotechnology companies to settle in, and also gathered star companies in the field of genetic editing and cell therapy segments such as Boya Centers, Tiankeya, and Runsheng cells.

Xie Jiasheng, executive president of Guangdong Medical Valley

Keynote Speech

The chief physician of the Department of Ophthalmology at Sun Yaxian Memorial Hospital of Sun Yat -sen University, Xiao Jianhui, a doctor of medicine, connected to the scene through online, and gave a detailed speech on the theme of eye health and anti -blind treatment technologies, elderly macular transsexual disease combined diagnosis and treatment strategies. I shared their own diagnosis and treatment experience and scientific research results from the ophthalmological diseases and work practice.

Xiao Jianhui, Chief PhD Medical PhD of Sun Yaxian Memorial Hospital, Sun Yixian Memorial Hospital of Sun Yat -sen University

AI+gene therapy one -stop solution

Ren Sheng, the person in charge of the Biological Gene therapy of the Eastern Industry, shared the theme of AI+gene therapy one -stop solution, and built a platform for the AI+disease prediction platform, AI+model construction platform (all -gene human -oriented mice), AI+AAV shell optimization platform , Ophthalmology Therapy CRO platform and other platforms have introduced detailed introductions.

Ren Sheng, the person in charge of the biological gene therapy

Overall solution of genetic diseases help CGT drug development

Liu Tianchi, a scientist of Jiaqi Medical Clinical Application, shared the overall solution of genetic diseases to help CGT drug development. He said that Jiaqi Medical actively responded to domestic alternative policies and combined with the genetic detection models of genetic diseases. For the output of the disease detection platform, the hospital carried out the detection and screening of clinical genetic genes in genetic diseases through the hospital to achieve precise treatment and regeneration guidance, and then provided a series of guarantee measures for subsequent auxiliary reproductive. And continuously optimize the genetic and variant factors of birth defects, comprehensive and rapid assessment of the genetic and fast evaluation, and create a one -stop solution close to clinical use to provide professional and clinical and reasonable molecular detection instruments, reagents and software for medical institutions at all levels. And provide services such as clinical personnel training, hospital consultation, and personalized genetic consultation.

Liu Tianchi, clinical application scientist of Jiaqian Medical Clinical Application

Regenerative Medicine Clinical Transformation Thinking and Practice

Zhang Zhiyong, a special expert in national talent engineering and chief scientist of China Science and Technology, shared the clinical transformation thinking and practice of recycled medicine -three -step strategy. He pointed out that regenerative medicine is expected to be the third treatment path after treatment and surgical treatment. Especially for congenital genetic defect diseases and acquired degenerative diseases. It mainly includes a variety of research areas such as stem cells, tissue engineering, cell therapy, and organ transplantation. Zhongke Ruiji focuses on the industrialization and clinical promotion of recycled medical technology. It is based on a number of renewable medical core technologies and key raw materials such as stem cell large -scale amplification, cell drug therapy, and clean compartment. And provide overall solutions.

Zhang Zhiyong, a special expert in major national talent engineering and chief scientist of China Science

Development and improvement of gene therapy delivery platform

With the accumulation of technology, the gene therapy industry is becoming mature, but gene delivery still has high technical barriers, becoming one of the important issues that plague the development of the industry. Yunzhou Biotechnology Ye Zhisheng said that gene therapy can be understood as the "good" gene to the cells, instead of "bad" genes, to supplement or correct the expression of related genes, thereby maintaining the normal physiological function of the body Essence This requires a special intermediary -gene delivery carrier. In order to break through the development bottleneck of the gene delivery industry, Yunzhou Biological has developed a full -chain gene delivery platform to meet the carrier customization, virus packaging, library construction screening, stabilizing cell plant construction, mRNA preparation, protein production, and CDMO services, which can meet customers. For different virus, adenovirus, adenovirus, adenovirus, HSV virus, and VSV virus, the application scope covers the entire life science and biomedical field. Ye Zhisheng, deputy general manager of Yunzhou Biotechnology

The development status and challenge of stem cell therapy drugs

Feng Xiaomin, the director of active analysis, in -depth sharing of the development and challenges of stem cell therapy drugs. She comprehensively analyzed the clinical trials of global stem cell therapy, the types of stem cell drugs and indications. A total of 50 drugs approved by stem cells around the world. Only 25 new drugs in China have entered clinical experiments.

Feng Xiaomin, director of active analysis of Boya albums

The application of rare disease data centers and AI in the diagnosis of genetic diseases

The types of rare diseases occupy a large proportion of human diseases. Dr. Huang Ying, Executive Secretary of the Tsinghua Pearl River Delta Research Institute of Artificial Intelligence Innovation Center, and the executive secretary of the Guangzhou Rare Disease Therapy Alliance, explained the database, focusing on the RDDC platform, and data. Integration, further optimization, and building rare disease data centers, more conveniently querying relevant disease information, and helping drug research and development.

Huang Ying, Executive Secretary of the Tsinghua Pearl River Delta Research Institute of Artificial Intelligence Innovation Center and the Standing Secretary of Guangzhou Rare Disease Therapy Alliance

Genetic therapy delivery guards

Yan Yisong, a medical expert in the Artificial Intelligence R & D Department of Sun Yat -sen University in Sun Yat -sen University, shared the theme of "Genetic Delivery -High -precision Eye Surgical Robot" based on the actual cases. He said that the precision requirements for micro -invasive surgery of the ophthalmology and challenges are huge. Weiming self -developed high -precision ophthalmology robots, exclusive development of stringing and co -structured robotic arm structure, greatly improving accuracy RCM control and end positioning. Small and flexible robotic arm and end actuator can achieve flexible replacement of surgical consumables during the operation, the largest Limit the natural operation form of the doctor.

Professor Yan Yisong, Medical Expert of the Artificial Intelligence R & D Department of Sun Yat -sen University in Sun Yat -sen University

Experts expressed their opinions around the theme in their respective fields, and conducted in -depth sharing. Participants at the scene also launched a heated exchange and discussion, and they expressed their full gains. At this point, cells and gene therapy drug development challenges and innovation solutions -the 21st China Medical Industry Summit Forum is successfully concluded. This event aims to gather high -end resources in innovative ecosystems in the field of biotechnology, explore the challenge of cell and gene therapy drug development challenges And innovative solution.

Source: China Economic News Network

- END -